Rapid Nexus Nanotech Wound Solutions, Inc.

Rapid Nexus Nanotech Wound Solutions Inc. is a clinical stage medtech company that has developed the world's first neuropathy and peri-wound healing product. Currently, there are no products made to repair damaged nerves due to peripheral neuropathy, leading to frequent costly amputations and patient limb replacements. Radiographic and visual evidence shows this patented technology closed combination hard and soft tissue wounds 500% faster than competitor products, even for patients with chronic wounds and diabetes. This breakthrough treatment has been refined into Hemastyl™, the first-ever wound healing product designed specifically for peri-wound care and neuropathy. What is Neuropathy and How Does It Affect Chronic Wounds? Neuropathy, often caused by diabetes, is nerve damage in the limbs that leads to chronic, non-healing wounds. This damage causes skin and muscle degeneration, sometimes resulting in necrosis. The resulting tissue breakdown creates wounds prone to infection, amputation, sepsis, and even death. In patient studies, Hemastyl™ achieved unprecedented closure rates averaging 95.5% across 22 high-risk wounds, some initially designated for amputation. This is the only technology that can solve this urgent global medical need, for which there's currently no other solution.

• Employees 5
• Founded 2020